AbbVie has advanced 3.80% to $253.38 since the July 15 report, reversing the prior breakdown and re-establishing proximity to the $254–$255 resistance zone. The move is supported by expanded European Commission approvals for Skyrizi and Maviret, while the pending $10.9 billion Apogee Therapeutics acquisition and upcoming July 31 Q2 earnings release define the near-term catalyst path. The investment thesis remains intact, though the stock now faces a critical technical test at previously invalidated resistance.
Key Updates
Since the July 15 report, AbbVie has appreciated 3.80% from $244.11 to $253.38, more than fully retracing the prior decline and invalidating the bearish breakdown below $248. The recovery occurs in the absence of new post-July 15 headlines, suggesting a technical rebound and continued digestion of the June 22 Apogee acquisition announcement and the June 23 expanded European approvals for Skyrizi and Maviret. The company is scheduled to report Q2 2026 earnings on July 31, 2026, which represents the next scheduled catalyst.
Current Trend
The YTD performance stands at +10.89%, with the 1-month return accelerating to +17.04% and the 6-month return at +18.38%. The 5-day trend of +2.17% confirms short-term momentum, while the 1-day decline of -0.44% suggests minor profit-taking near resistance. The stock has transitioned from the July 15 low back into the upper portion of its recent range, indicating that the prevailing intermediate-term uptrend remains active.
Investment Thesis
The thesis rests on AbbVie's ability to drive growth through its immunology franchise—specifically Rinvoq and Skyrizi, which are expected to generate combined revenue exceeding $31 billion this year—while diversifying via M&A. The $10.9 billion acquisition of Apogee Therapeutics adds zumilokibart, a Phase 3 IL-13 inhibitor targeting the atopic dermatitis market dominated by Dupixent, directly addressing portfolio concentration risk post-Humira. Expanded European pediatric indications for Skyrizi and Maviret extend the addressable market, supporting long-term revenue durability. Near-term catalysts include the July 31 Q2 earnings release and integration progress on the Apogee deal, expected to close in Q3 2026.
Thesis Status
The thesis remains constructive. The recovery from $244.11 to $253.38 demonstrates resilient demand for the shares following the July 1–15 pullback. Fundamental drivers—immunology revenue scale, regulatory expansions in Europe, and pipeline augmentation via Apogee—have not changed. However, the stock is again testing the $254–$255 area, which previously triggered reversals; a confirmed breakout on volume would strengthen the bullish case, whereas rejection would signal continued range-bound action.
Key Drivers
Primary catalysts include: (1) the July 31, 2026 Q2 earnings release and conference call, which will provide updated financial metrics and management guidance (PR Newswire); (2) expanded European Commission approval for Skyrizi in pediatric plaque psoriasis and Maviret in acute hepatitis C, broadening the addressable patient population (Morningstar); (3) the $10.9 billion acquisition of Apogee Therapeutics, adding the Phase 3 asset zumilokibart to compete in the atopic dermatitis market, funded via debt and expected to close in Q3 2026 (Morningstar, WSJ); (4) combined Rinvoq and Skyrizi revenue projected to exceed $31 billion in 2026, underpinning near-term cash flow generation (Morningstar).
Technical Analysis
Current price action at $253.38 positions AbbVie just below the prior multi-week high zone of $254–$255, which was briefly exceeded on July 7 ($254.76) and June 30 ($254.31) before the July 1–15 pullback. The July 15 low of $244.11 now serves as near-term support, with the July 1 low near $248 acting as an intermediate floor. A sustained close above $255 would confirm a bullish breakout and open the path toward new highs, while failure at this level risks a return to the $244–$248 support band. Volume characteristics around the July 31 earnings release will be critical in validating any directional resolution.
Bull Case
- AbbVie expects combined revenue from Rinvoq and Skyrizi to top $31 billion this year, providing a durable, cash-generative immunology base that funds dividends and M&A (Morningstar).
- The Apogee Therapeutics acquisition adds zumilokibart, a Phase 3 IL-13 inhibitor for atopic dermatitis, directly targeting the large Dupixent market and diversifying the immunology pipeline beyond Humira legacy (Morningstar).
- Expanded European approvals for Skyrizi (pediatric plaque psoriasis) and Maviret (acute hepatitis C, ages 3+) broaden the addressable market and extend the commercial runway for two established franchises (Morningstar).
- The company maintains financial flexibility to pursue additional business development while affirming its commitment to dividend payments, signaling balance-sheet discipline despite the $10.9 billion deal (Morningstar).
- Strong YTD (+10.89%) and 1-month (+17.04%) momentum, coupled with the recovery from the July 15 low, indicates sustained institutional demand and a constructive intermediate-term trend.
Bear Case
- The Apogee acquisition is dilutive to adjusted EPS by an estimated 14 cents in 2024 and 46 cents in 2027, with no earnings accretion expected until 2032, creating a multi-year drag on profitability metrics (Morningstar).
- The $10.9 billion deal is funded through debt, increasing leverage at a time of elevated interest rates and potentially constraining financial flexibility if integration or clinical outcomes disappoint (Morningstar).
- AbbVie paid a 49% premium for Apogee ($135.11 per share vs. $90.38 close), raising execution risk and the bar for zumilokibart to achieve commercial success competitive with Dupixent (Morningstar).
- The stock has twice failed to hold above the $254–$255 zone (June 30 and July 7), and the current retest faces resistance; a third rejection would confirm a lower-risk selling zone and potential range-bound price action.
- Humira biosimilar erosion continues to weigh on legacy revenue, requiring flawless execution from Skyrizi and Rinvoq to offset structural decline in the former flagship franchise.